Celldex Stock Falls On Unusually High Volume (CLDX)

Celldex Therapeutics (Nasdaq:CLDX) is trading at unusually high volume Monday with 3.3 million shares changing hands. It is currently at two times its average daily volume and trading down 83 cents (-3.9%).
By TheStreet Wire ,

NEW YORK (

TheStreet

) --

Celldex Therapeutics

(Nasdaq:

CLDX

) is trading at unusually high volume Monday with 3.3 million shares changing hands. It is currently at two times its average daily volume and trading down 83 cents (-3.9%) at $20.44 as of 11:45 a.m. ET.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Celldex has a market cap of $1.51 billion and is part of the health care sector and drugs industry. Shares are up 217% year to date as of the close of trading on Friday.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States.

TheStreet Ratings rates

Celldex

as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and weak operating cash flow. You can view the full

Celldex Ratings Report

.

See all heavy volume stocks in our

stocks moving on unusual volume list

or get investment ideas from our

investment research center

.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

.

null

Loading ...